Loading...
Header Logo
Keywords
Last Name
Institution

JAFFER A AJANI

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019 Mar 11. PMID: 30854619.
      View in: PubMed
    2. van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel). 2019 Feb 05; 11(2). PMID: 30764578.
      View in: PubMed
    3. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2019 Jan 31. PMID: 30720506.
      View in: PubMed
    4. Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019 Jan 31. PMID: 30706247.
      View in: PubMed
    5. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 Jan 24. PMID: 30680477.
      View in: PubMed
    6. Harada K, Abdelhakeem AAF, Ajani JA. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nat Rev Clin Oncol. 2019 Jan; 16(1):9-10. PMID: 30291292.
      View in: PubMed
    7. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019 Jan; 79(1):63-74. PMID: 30617958.
      View in: PubMed
    8. Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019 Feb; 108:17-24. PMID: 30592991.
      View in: PubMed
    9. Iwatsuki M, Harada K, Baba H, Ajani JA. Higher rate of colon polyp detection aided by an artificial intelligent software. Transl Gastroenterol Hepatol. 2018; 3:106. PMID: 30701213.
      View in: PubMed
    10. Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018; 12:883. PMID: 30679950.
      View in: PubMed
    11. Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA. Cancer stem cells in esophageal cancer and response to therapy. Cancer. 2018 Oct 15; 124(20):3962-3964. PMID: 30368777.
      View in: PubMed
    12. Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2019 Jan; 3(1):43-49. PMID: 30697609.
      View in: PubMed
    13. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-ß Superfamily. Cell Syst. 2018 Oct 24; 7(4):422-437.e7. PMID: 30268436.
      View in: PubMed
    14. Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 Sep 18; 8(1):14006. PMID: 30228315.
      View in: PubMed
    15. Ajani JA, Bhutani MS, Swisher SG. Oesophageal preservation in locally advanced oesophageal cancer. Lancet Oncol. 2018 Sep; 19(9):e430. PMID: 30191840.
      View in: PubMed
    16. Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018; 7. PMID: 30228868.
      View in: PubMed
    17. Harada K, Song S, Ajani JA. Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. Oncoscience. 2018 Jul; 5(7-8):214-215. PMID: 30234141.
      View in: PubMed
    18. Song S, Ajani JA. Reply. Gastroenterology. 2018 09; 155(3):934-935. PMID: 30098926.
      View in: PubMed
    19. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 Aug; 268(2):289-295. PMID: 28628563.
      View in: PubMed
    20. Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 Nov; 22(11):2013-2019. PMID: 30054780.
      View in: PubMed
    21. Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, Mansfield P, Ajani J, Badgwell BD. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730. PMID: 29987602.
      View in: PubMed
    22. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728. PMID: 29949666.
      View in: PubMed
    23. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67. PMID: 29878364.
      View in: PubMed
    24. Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29. PMID: 29859338.
      View in: PubMed
    25. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90. PMID: 29843157.
      View in: PubMed
    26. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017. PMID: 29748883.
      View in: PubMed
    27. Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018 May; 24(5):556-562. PMID: 29736026.
      View in: PubMed
    28. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013. PMID: 29730720.
      View in: PubMed
    29. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777. PMID: 29725014.
      View in: PubMed
    30. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353. PMID: 29705797.
      View in: PubMed
    31. Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev. 2018 May; 66:104-113. PMID: 29730461.
      View in: PubMed
    32. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 Aug; 22(8):1325-1333. PMID: 29679346.
      View in: PubMed
    33. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 Apr; 41(4):321-325. PMID: 26908161.
      View in: PubMed
    34. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med. 2018 Mar; 4(1):8-17. PMID: 29756119.
      View in: PubMed
    35. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, Ajani J, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 Jul; 156(1):406-413.e3. PMID: 29605441.
      View in: PubMed
    36. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus. 2018 Mar 01; 31(3). PMID: 29579257.
      View in: PubMed
    37. Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 Mar 01; 124(5):998-1007. PMID: 29393964.
      View in: PubMed
    38. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2018 Feb; 6(4):80. PMID: 29666803.
      View in: PubMed
    39. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. J Thorac Dis. 2018 Feb; 10(2):699-702. PMID: 29607137.
      View in: PubMed
    40. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 Feb; 13(1):99-106. PMID: 29218623.
      View in: PubMed
    41. Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med. 2018 Feb; 6(4):78. PMID: 29666801.
      View in: PubMed
    42. Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. Gastroenterology. 2018 04; 154(5):1524-1537.e6. PMID: 29274868.
      View in: PubMed
    43. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160. PMID: 29248170.
      View in: PubMed
    44. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018 01; 7(1):123-133. PMID: 29239137.
      View in: PubMed
    45. Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, Ajani JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. J Surg Oncol. 2018 Mar; 117(4):707-709. PMID: 29228462.
      View in: PubMed
    46. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018 01; 18(1):19-38. PMID: 29202614.
      View in: PubMed
    47. Mizrak Kaya D, Nogueras-González GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, Ajani JA. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684. PMID: 29205363.
      View in: PubMed
    48. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol. 2017 Dec; 8(6):1009-1017. PMID: 29299361.
      View in: PubMed
    49. Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, Ajani JA. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2018 02; 17(2):443-454. PMID: 29167315.
      View in: PubMed
    50. Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61. PMID: 29136404.
      View in: PubMed
    51. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017 10 19; 8(1):1050. PMID: 29051489.
      View in: PubMed
    52. In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9. PMID: 28948368.
      View in: PubMed
    53. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017 Nov; 24(12):3683-3691. PMID: 28895113.
      View in: PubMed
    54. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113. PMID: 28885712.
      View in: PubMed
    55. Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 01; 28(9):2142-2148. PMID: 28911091.
      View in: PubMed
    56. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol. 2017 Sep 01; 28(9):2077-2085. PMID: 28430862.
      View in: PubMed
    57. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570. PMID: 28819789.
      View in: PubMed
    58. Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017 08 15; 10(1):149. PMID: 28810883.
      View in: PubMed
    59. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40. PMID: 28801853.
      View in: PubMed
    60. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344. PMID: 28799004.
      View in: PubMed
    61. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017 Jul 26. PMID: 28747339.
      View in: PubMed
    62. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655. PMID: 28728163.
      View in: PubMed
    63. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666. PMID: 29280460.
      View in: PubMed
    64. Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 10; 16(10):2215-2222. PMID: 28716815.
      View in: PubMed
    65. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Oct 06; 8(46):81430-81440. PMID: 29113402.
      View in: PubMed
    66. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248. PMID: 28683449.
      View in: PubMed
    67. Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135. PMID: 28685276.
      View in: PubMed
    68. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676. PMID: 29280461.
      View in: PubMed
    69. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5671-5678. PMID: 28655793.
      View in: PubMed
    70. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512. PMID: 28643069.
      View in: PubMed
    71. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83. PMID: 28643144.
      View in: PubMed
    72. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 01; 3:17036. PMID: 28569272.
      View in: PubMed
    73. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. 2017 Oct 03; 8(45):79356-79365. PMID: 29108314.
      View in: PubMed
    74. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710. PMID: 28404924.
      View in: PubMed
    75. Elimova E, Lin Q, Song S, Ajani JA. Current status of ramucirumab in gastroesophageal adenocarcinoma. Future Oncol. 2017 Aug; 13(18):1585-1592. PMID: 28436242.
      View in: PubMed
    76. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res. 2017; 6:501. PMID: 28491289.
      View in: PubMed
    77. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 05; 18(5):640-653. PMID: 28343975.
      View in: PubMed
    78. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687. PMID: 28332034.
      View in: PubMed
    79. Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017; 7(3):473-483. PMID: 28401005.
      View in: PubMed
    80. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017 Feb 07; 23(5):751-762. PMID: 28223720.
      View in: PubMed
    81. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017 Mar; 10(3):263-271. PMID: 28094573.
      View in: PubMed
    82. Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, Ajani JA, Wu X. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. Carcinogenesis. 2017 02 01; 38(2):162-167. PMID: 28062409.
      View in: PubMed
    83. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol. 2017 Apr; 13(10):919-934. PMID: 28067073.
      View in: PubMed
    84. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, Ajani JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60. PMID: 28189209.
      View in: PubMed
    85. Bartley AN, Washington MK, Ismaila N, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017 01; 13(1):53-57. PMID: 27907277.
      View in: PubMed
    86. Doll CM, Moughan J, Klimowicz A, Ho CK, Kornaga EN, Lees-Miller SP, Ajani JA, Crane CH, Kachnic LA, Okawara GS, Berk LB, Roof KS, Becker MJ, Grisell DL, Ellis RJ, Sperduto PW, Marsa GW, Guha C, Magliocco AM. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):554-562. PMID: 28126304.
      View in: PubMed
    87. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016 Dec; 146(6):647-669. PMID: 28077399.
      View in: PubMed
    88. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363. PMID: 27841667.
      View in: PubMed
    89. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb; 35(4):446-464. PMID: 28129524.
      View in: PubMed
    90. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 Feb; 35(4):475-477. PMID: 28129519.
      View in: PubMed
    91. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382. PMID: 27794500.
      View in: PubMed
    92. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965. PMID: 27778127.
      View in: PubMed
    93. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301. PMID: 27770339.
      View in: PubMed
    94. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol. 2016 12; 17(12):1628-1629. PMID: 27776842.
      View in: PubMed
    95. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-ß-Catenin Signaling in Colorectal Cancer. EBioMedicine. 2016 Nov; 13:113-124. PMID: 27789274.
      View in: PubMed
    96. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. 2016 Oct 10. PMID: 27718753.
      View in: PubMed
    97. Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374. PMID: 27729298.
      View in: PubMed
    98. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer. 2017 Mar; 20(Suppl 1):92-101. PMID: 27718136.
      View in: PubMed
    99. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 10; 14(10):1286-1312. PMID: 27697982.
      View in: PubMed
    100. Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, Ajani JA, Chen J, Lee JS, Song S, Johnson RL. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology. 2016 11; 64(5):1757-1772. PMID: 27531557.
      View in: PubMed
    101. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma? Expert Opin Pharmacother. 2016 12; 17(18):2371-2374. PMID: 27652930.
      View in: PubMed
    102. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, Ajani JA, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6228-6235. PMID: 27654712.
      View in: PubMed
    103. Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982. PMID: 27623234.
      View in: PubMed
    104. Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc. 2016 09; 91(9):1307-18. PMID: 27594190.
      View in: PubMed
    105. Elimova E, Song S, Shimodaira Y, Lin Q, Ajani JA. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol. 2016 11; 23(12):3786-3791. PMID: 27503493.
      View in: PubMed
    106. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016 Aug; 7(4):499-505. PMID: 27563438; PMCID: PMC4963369.
    107. Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, Ajani JA. Evolution of gastric surgery techniques and outcomes. Chin J Cancer. 2016 07 26; 35(1):69. PMID: 27460019; PMCID: PMC4962398.
    108. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606. PMID: 27439746.
      View in: PubMed
    109. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337. PMID: 27384751.
      View in: PubMed
    110. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60. PMID: 27120436; PMCID: PMC4949128 [Available on 04/28/17].
    111. Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47. PMID: 27046280; PMCID: PMC4870109 [Available on 04/06/17].
    112. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55. PMID: 26868957.
      View in: PubMed
    113. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 Feb; 14(2):173-9. PMID: 26850487.
      View in: PubMed
    114. Shimodaira Y, Harada K, Lin Q, Ajani JA. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Ann Transl Med. 2016 Jan; 4(2):38. PMID: 26889491; PMCID: PMC4731594.
    115. Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. Am Soc Clin Oncol Educ Book. 2016; 35:104-11. PMID: 27249691.
      View in: PubMed
    116. Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1. PMID: 26680311.
      View in: PubMed
    117. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92. PMID: 26560689.
      View in: PubMed
    118. Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35. PMID: 26603684.
      View in: PubMed
    119. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32. PMID: 26564243.
      View in: PubMed
    120. Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology. 2016; 90(1):10-20. PMID: 26492090.
      View in: PubMed
    121. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7. PMID: 26482869.
      View in: PubMed
    122. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10. PMID: 26393501.
      View in: PubMed
    123. Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22; 6(28):25883-96. PMID: 26317542.
      View in: PubMed
    124. Elimova E, Ajani JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? J Clin Oncol. 2015 Oct 01; 33(28):3085-91. PMID: 26324361.
      View in: PubMed
    125. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501.
      View in: PubMed
    126. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606. PMID: 26296479; PMCID: PMC4820399.
    127. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20. PMID: 26159599; PMCID: PMC4580507.
    128. Elimova E, Ajani JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol. 2015 Jul 20; 33(21):2410. PMID: 26077236.
      View in: PubMed
    129. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62. PMID: 26059652.
      View in: PubMed
    130. Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausová J, Van Laethem JL, Cascinu S, Ajani JA. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17. PMID: 25707610.
      View in: PubMed
    131. Shimodaira Y, Elimova E, Wadhwa R, Shiozaki H, Charalampakis N, Planjery V, Rogers JE, Song S, Ajani JA. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs. 2015; 3(6):737-746. PMID: 27570714.
      View in: PubMed
    132. Sanchez-Espiridion B, Liang D, Ajani JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1730-1737.e9. PMID: 25998788; PMCID: PMC4596233 [Available on 10/01/16].
    133. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90. PMID: 26002780.
      View in: PubMed
    134. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81. PMID: 25872485.
      View in: PubMed
    135. Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, Ajani JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother. 2015 May; 16(7):955-60. PMID: 25850442; PMCID: PMC4743879.
    136. Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, Ajani JA. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29. PMID: 26052595.
      View in: PubMed
    137. Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9. PMID: 25765719.
      View in: PubMed
    138. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90. PMID: 25739674.
      View in: PubMed
    139. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6. PMID: 25765098.
      View in: PubMed
    140. Ajani JA, Song S, Hochster HS, Steinberg IB. Introduction. Semin Oncol. 2015 Apr; 42 Suppl 1:S1-2. PMID: 25839663.
      View in: PubMed
    141. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52. PMID: 25642337; PMCID: PMC4294819.
    142. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
      View in: PubMed
    143. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015 Apr; 42 Suppl 1:S3-17. PMID: 25839664.
      View in: PubMed
    144. Ajani JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how? J Natl Compr Canc Netw. 2015 Jan; 13(1):2-3. PMID: 25583763.
      View in: PubMed
    145. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015 Nov; 64(11):1721-31. PMID: 25385008; PMCID: PMC4680172.
    146. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47. PMID: 25320502; PMCID: PMC4194548.
    147. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1224-35. PMID: 25240821.
      View in: PubMed
    148. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5. PMID: 25225435; PMCID: PMC4195852.
    149. Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, Ajani J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41. PMID: 25091571; PMCID: PMC4239178.
    150. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
      View in: PubMed
    151. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44. PMID: 25099446.
      View in: PubMed
    152. Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57. PMID: 25003289; PMCID: PMC4100249.
    153. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71. PMID: 25038008.
      View in: PubMed
    154. Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, Ajani JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8. PMID: 24990617.
      View in: PubMed
    155. Sun Y, Gu J, Ajani JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. Cancer. 2014 Oct 01; 120(19):3040-8. PMID: 24962126.
      View in: PubMed
    156. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9. PMID: 24925190; PMCID: PMC4105702.
    157. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014 Aug 01; 74(15):4170-82. PMID: 24906622.
      View in: PubMed
    158. Sudo K, Elimova E, Skinner HD, Hofstetter WL, Ajani JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 01; 32(19):2112-3. PMID: 24868018.
      View in: PubMed
    159. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014 Aug; 45(2):567-74. PMID: 24859412.
      View in: PubMed
    160. Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol. 2014 Sep; 21(9):2815-6. PMID: 24756809.
      View in: PubMed
    161. Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, Ajani JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. Mol Carcinog. 2015 Sep; 54(9):880-8. PMID: 24756984.
      View in: PubMed
    162. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823; PMCID: PMC4039117.
    163. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79. PMID: 24605771.
      View in: PubMed
    164. Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, Muddasani R, Lu V, Tan D, Ajani JA, Wei Q. Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2015 Jun; 54(6):449-58. PMID: 24302553.
      View in: PubMed
    165. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14. PMID: 24197760.
      View in: PubMed
    166. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8. PMID: 24199704.
      View in: PubMed
    167. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755.
      View in: PubMed
    168. Dhupar R, Correa AM, Ajani J, Betancourt S, Mehran RJ, Swisher SG, Hofstetter WL. Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 2014 Nov-Dec; 27(8):770-6. PMID: 24152134.
      View in: PubMed
    169. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10. PMID: 24145339.
      View in: PubMed
    170. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55. PMID: 24061039; PMCID: PMC3927982.
    171. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7. PMID: 24051869.
      View in: PubMed
    172. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 01; 31(31):3935-43. PMID: 24043745.
      View in: PubMed
    173. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45. PMID: 24035327; PMCID: PMC3938865.
    174. Li Y, Liu Z, Liu H, Wang LE, Tan D, Ajani JA, Wei QY. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One. 2013; 8(9):e71994. PMID: 24023723; PMCID: PMC3759385.
    175. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9. PMID: 23994746.
      View in: PubMed
    176. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2013 Dec; 34(12):2750-6. PMID: 23996928; PMCID: PMC3845893.
    177. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663.
      View in: PubMed
    178. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91. PMID: 23845841; PMCID: PMC3786201.
    179. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using ?-H2AX assay. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1797-804. PMID: 23904462; PMCID: PMC3824382.
    180. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24. PMID: 23899532.
      View in: PubMed
    181. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9. PMID: 23860252.
      View in: PubMed
    182. Ajani JA. Challenges imposed by the complexity of cancer genome. Lancet Oncol. 2013 Jul; 14(8):e291-2. PMID: 23816294.
      View in: PubMed
    183. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 2013 Nov; 34(11):2521-4. PMID: 23803692; PMCID: PMC3810839.
    184. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95. PMID: 23718298.
      View in: PubMed
    185. Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69. PMID: 23715646; PMCID: PMC4998180.
    186. Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, Ajani JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PLoS One. 2013; 8(5):e64973. PMID: 23724109; PMCID: PMC3665554.
    187. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46. PMID: 23667204.
      View in: PubMed
    188. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168; PMCID: PMC3740061.
    189. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51. PMID: 23355076.
      View in: PubMed
    190. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-ß adaptor ß2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 01; 73(7):2159-69. PMID: 23536563; PMCID: PMC3745222.
    191. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205. PMID: 23466817; PMCID: PMC3608471.
    192. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69. PMID: 23639645.
      View in: PubMed
    193. Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15. PMID: 23350713.
      View in: PubMed
    194. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70. PMID: 23303654.
      View in: PubMed
    195. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):60-6. PMID: 23307982.
      View in: PubMed
    196. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6. PMID: 23247658; PMCID: PMC3629896.
    197. Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2. PMID: 23221793.
      View in: PubMed
    198. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013 Feb; 10(2):109-18. PMID: 23165235; PMCID: PMC3855852.
    199. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51. PMID: 23150707; PMCID: PMC3515768.
    200. Das P, Strong VE, Ajani JA. Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options. Gastrointest Cancer Res. 2012 Nov; 5(6):203-4. PMID: 23293702; PMCID: PMC3533849.
    201. Swisher S, Ajani J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. Lancet. 2012 Sep 08; 380(9845):883; author reply 885-6. PMID: 22959377.
      View in: PubMed
    202. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9. PMID: 22950385.
      View in: PubMed
    203. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4. PMID: 22964903; PMCID: PMC3832345.
    204. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol. 2012 Oct; 5(5):355-60. PMID: 26181075.
      View in: PubMed
    205. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
      View in: PubMed
    206. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov; 48(16):2941-53. PMID: 22921186.
      View in: PubMed
    207. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85. PMID: 22867894; PMCID: PMC3923623.
    208. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404. PMID: 22853875; PMCID: PMC3869451.
    209. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4. PMID: 22825372.
      View in: PubMed
    210. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-42. PMID: 22831985; PMCID: PMC3457750.
    211. Jiang Y, Ajani JA. Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol. 2012 Jul; 24(4):448-53. PMID: 22581355.
      View in: PubMed
    212. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11. PMID: 22735568.
      View in: PubMed
    213. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51. PMID: 22677933.
      View in: PubMed
    214. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 01; 30(19):2327-33. PMID: 22585691.
      View in: PubMed
    215. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87. PMID: 22439934; PMCID: PMC3350095.
    216. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9. PMID: 22436793; PMCID: PMC3795392.
    217. Hayashi Y, Blum MA, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9. PMID: 22488092.
      View in: PubMed
    218. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51. PMID: 22417808; PMCID: PMC3923631.
    219. Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5. PMID: 22392288.
      View in: PubMed
    220. Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res. 2012 Mar; 5(2):49-57. PMID: 22690258.
      View in: PubMed
    221. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20. PMID: 22331947.
      View in: PubMed
    222. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13. PMID: 22328056.
      View in: PubMed
    223. Ajani JA, Swisher SG. Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 2012 Jan; 19(1):3-4. PMID: 21989665.
      View in: PubMed
    224. Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012 Sep 01; 118(17):4346-53. PMID: 22213102; PMCID: PMC3831524.
    225. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20. PMID: 22172216.
      View in: PubMed
    226. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22. PMID: 22150920.
      View in: PubMed
    227. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):581-6. PMID: 22137021.
      View in: PubMed
    228. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012 Feb; 75(2):242-53. PMID: 22115605.
      View in: PubMed
    229. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62. PMID: 21992792; PMCID: PMC3237863.
    230. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40. PMID: 22565611; PMCID: PMC3747650.
    231. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3. PMID: 21962263; PMCID: PMC4041623.
    232. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500. PMID: 21985847.
      View in: PubMed
    233. Ajani JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. PMID: 22211134; PMCID: PMC3170070.
    234. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87. PMID: 21900218.
      View in: PubMed
    235. Ajani JA. Crescendos and decrescendos: gastric and esophageal cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):811-3. PMID: 21900215.
      View in: PubMed
    236. Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, Ajani JA. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11. PMID: 21900220.
      View in: PubMed
    237. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. PMID: 21788567.
      View in: PubMed
    238. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53. PMID: 21602659.
      View in: PubMed
    239. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67. PMID: 21365188; PMCID: PMC4086148.
    240. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26. PMID: 21675835.
      View in: PubMed
    241. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3. PMID: 21606421.
      View in: PubMed
    242. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res. 2011 May; 4(3):96-105. PMID: 22043325; PMCID: PMC3201643.
    243. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 Aug; 141(2):476-85, 485.e1-11. PMID: 21684283; PMCID: PMC3152688.
    244. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72. PMID: 21507583; PMCID: PMC3796353.
    245. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1336-42. PMID: 21470796; PMCID: PMC4086056.
    246. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33. PMID: 21456015; PMCID: PMC3144261.
    247. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011 Apr 01; 17(7):1850-7. PMID: 21447720; PMCID: PMC3078023.
    248. Ajani JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. Gastrointest Cancer Res. 2011 Mar; 4(2):39. PMID: 21673873; PMCID: PMC3109889.
    249. Cohen DJ, Ajani J. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39. PMID: 21226634.
      View in: PubMed
    250. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011 Jan 01; 128(1):132-43. PMID: 20309880; PMCID: PMC2937084.
    251. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74. PMID: 21123005; PMCID: PMC4028959.
    252. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010 Nov 30; 5(11):e15074. PMID: 21152079; PMCID: PMC2994829.
    253. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, Ajani JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27. PMID: 21136578.
      View in: PubMed
    254. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010 Nov; 26(6):640-6. PMID: 20827183.
      View in: PubMed
    255. Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, Ajani JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. BMC Med Inform Decis Mak. 2010 Oct 26; 10:65. PMID: 20977768; PMCID: PMC2987967.
    256. Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30. PMID: 20960497; PMCID: PMC3080168.
    257. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6. PMID: 20956625; PMCID: PMC3018356.
    258. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94. PMID: 20629031.
      View in: PubMed
    259. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9. PMID: 20732514.
      View in: PubMed
    260. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13. PMID: 20564111; PMCID: PMC3831519.
    261. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      View in: PubMed
    262. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9. PMID: 20803613.
      View in: PubMed
    263. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
      View in: PubMed
    264. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41. PMID: 20701442.
      View in: PubMed
    265. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86. PMID: 20651033; PMCID: PMC3932797.
    266. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 01; 116(11):2511-8. PMID: 20301114.
      View in: PubMed
    267. Shah MA, Ajani JA. Gastric cancer--an enigmatic and heterogeneous disease. JAMA. 2010 May 05; 303(17):1753-4. PMID: 20442394.
      View in: PubMed
    268. Ajani JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1. PMID: 20502055.
      View in: PubMed
    269. Ajani JA. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol. 2010 May 20; 28(15):e243-4; author reply e245. PMID: 20368554.
      View in: PubMed
    270. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63. PMID: 20143431.
      View in: PubMed
    271. Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, Ajani JA. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25. PMID: 20410334.
      View in: PubMed
    272. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):378-409. PMID: 20410333.
      View in: PubMed
    273. Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56. PMID: 20339140; PMCID: PMC2857801.
    274. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
      View in: PubMed
    275. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53. PMID: 20159816.
      View in: PubMed
    276. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan; 8(1):135-44. PMID: 20064295.
      View in: PubMed
    277. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
      View in: PubMed
    278. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009 Oct 16; 9:77. PMID: 19835575; PMCID: PMC2771032.
    279. Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8. PMID: 19562780.
      View in: PubMed
    280. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5744-52. PMID: 19737949; PMCID: PMC2745487.
    281. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21. PMID: 19734842.
      View in: PubMed
    282. Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S58-61. PMID: 20011567; PMCID: PMC2791384.
    283. Ajani JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S79. PMID: 20011571; PMCID: PMC2791378.
    284. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009 Aug 15; 115(16):3609-17. PMID: 19526592.
      View in: PubMed
    285. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8. PMID: 19458557.
      View in: PubMed
    286. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47. PMID: 19635226.
      View in: PubMed
    287. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
    288. Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res. 2009 Jun 30; 28:94. PMID: 19566948; PMCID: PMC2717936.
    289. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):816-23. PMID: 19525073; PMCID: PMC3696888.
    290. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal. 2009 May; 11(5):1083-95. PMID: 19187006; PMCID: PMC2842128.
    291. Lagaly R, Horak A, Lee JH, Mansfield PF, Ajani JA. Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res. 2009 May; 3(3):115-7. PMID: 19626154.
      View in: PubMed
    292. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res (Phila). 2009 May; 2(5):459-65. PMID: 19401529; PMCID: PMC2701666.
    293. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105. PMID: 19399614.
      View in: PubMed
    294. Ajani JA. Chemotherapy and radiation resistance: version 2.0. J Clin Oncol. 2009 Jun 01; 27(16):2735-6; author reply 2737-8. PMID: 19398570.
      View in: PubMed
    295. Bolton WD, Hofstetter WL, Francis AM, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6. PMID: 19660349.
      View in: PubMed
    296. Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85. PMID: 19156915.
      View in: PubMed
    297. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9. PMID: 19289262.
      View in: PubMed
    298. Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, Ajani JA, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis. 2009 May; 30(5):785-92. PMID: 19270000; PMCID: PMC2675653.
    299. Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am. 2009 Mar; 38(1):183-8, x. PMID: 19327575.
      View in: PubMed
    300. Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol. 2009 Mar; 5(2):157-61. PMID: 19284374.
      View in: PubMed
    301. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009 Feb; 13(1):49-59. PMID: 19201649.
      View in: PubMed
    302. Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009 Apr; 16(4):878-86. PMID: 19194759.
      View in: PubMed
    303. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30. PMID: 19130466.
      View in: PubMed
    304. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16. PMID: 19117343.
      View in: PubMed
    305. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009 Feb 20; 27(6):857-71. PMID: 19164214; PMCID: PMC2738430.
    306. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21. PMID: 19139424; PMCID: PMC2667813.
    307. Ajani JA. Preoperative therapy for potentially resectable localized gastric cancer. Gastrointest Cancer Res. 2009 Jan; 3(1):36-7. PMID: 19343137.
      View in: PubMed
    308. Yin M, Hu Z, Tan D, Ajani JA, Wei Q. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res. 2009 Jan 01; 1(1):44-54. PMID: 19966937; PMCID: PMC2776284.
    309. Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009; 69(18):2533-40. PMID: 19943706.
      View in: PubMed
    310. Ajani JA, Izzo JG, Lee JS. Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol. 2009 Jan 01; 27(1):162-3; author reply 163. PMID: 19047300.
      View in: PubMed
    311. Cen P, Correa AM, Lee JH, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41. PMID: 19021684.
      View in: PubMed
    312. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32. PMID: 19021681.
      View in: PubMed
    313. Tetzlaff ED, Cheng JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008 Nov; 2(6):267-72. PMID: 19259275; PMCID: PMC2632566.
    314. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 2008 Nov; 1(6):460-9. PMID: 19138993; PMCID: PMC2768267.
    315. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45. PMID: 18759326.
      View in: PubMed
    316. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6(9):818-49. PMID: 18926093.
      View in: PubMed
    317. Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct; 4(5):999-1007. PMID: 19209281; PMCID: PMC2621422.
    318. Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw. 2008 Oct; 6(9):813-4. PMID: 18998257.
      View in: PubMed
    319. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8. PMID: 18623381.
      View in: PubMed
    320. Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008 Oct 07; 99(7):1195; author reply 1196. PMID: 18766183; PMCID: PMC2567093.
    321. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11. PMID: 18670347.
      View in: PubMed
    322. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008 Sep 01; 113(5):945-55. PMID: 18623382.
      View in: PubMed
    323. Ajani JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? Nat Clin Pract Oncol. 2008 Sep; 5(9):508-9. PMID: 18628737.
      View in: PubMed
    324. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 01; 26(28):4551-6. PMID: 18574157; PMCID: PMC2653130.
    325. Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008 Jul; 31(7):360-1. PMID: 18596381.
      View in: PubMed
    326. Ajani JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):414-5. PMID: 18560397.
      View in: PubMed
    327. Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun; 8(6):975-91. PMID: 18533807.
      View in: PubMed
    328. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008 Jul; 12(3):253-68. PMID: 18501674.
      View in: PubMed
    329. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008; 21(7):575-81. PMID: 18459989.
      View in: PubMed
    330. Ajani JA, Schmoll HJ. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2008 May; 2(3 Suppl):S47-50. PMID: 19352469; PMCID: PMC2664914.
    331. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):167-72. PMID: 18406886.
      View in: PubMed
    332. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21. PMID: 18430910.
      View in: PubMed
    333. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, Huang P, Ajani J, Hung MC. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 2008 Apr 15; 68(8):2632-40. PMID: 18413730; PMCID: PMC2377413.
    334. Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70. PMID: 18398613.
      View in: PubMed
    335. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23. PMID: 18323556.
      View in: PubMed
    336. Baker J, Ajani JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. Eur J Oncol Nurs. 2008 Jul; 12(3):227-32. PMID: 18329956.
      View in: PubMed
    337. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7. PMID: 18205187.
      View in: PubMed
    338. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar; 13(1):135-44. PMID: 18321153.
      View in: PubMed
    339. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol. 2008 Mar; 3(3):277-82. PMID: 18317071.
      View in: PubMed
    340. Cen P, Tetzlaff ED, Ajani JA. Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results. Ther Clin Risk Manag. 2008 Feb; 4(1):137-40. PMID: 18728703; PMCID: PMC2503649.
    341. Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, Ajani JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 01; 112(3):503-10. PMID: 18072264.
      View in: PubMed
    342. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res. 2008 Jan; 2(1):10-4. PMID: 19259318; PMCID: PMC2630809.
    343. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7. PMID: 17899453.
      View in: PubMed
    344. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7. PMID: 18164837; PMCID: PMC4741525.
    345. Ajani JA. The area between the curves gets no respect: is it because of the median madness? J Clin Oncol. 2007 Dec 01; 25(34):5531. PMID: 18048834.
      View in: PubMed
    346. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90. PMID: 17896785.
      View in: PubMed
    347. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25. PMID: 18059229.
      View in: PubMed
    348. Goldberg RM, Marshall JL, Ajani JA, Philip PA, O'Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S13-6. PMID: 19330058; PMCID: PMC2659796.
    349. Kachnic LA, Ajani JA, Philip PA. Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S4-7. PMID: 19330059; PMCID: PMC2659792.
    350. Hochster HS, O'Reilly EM, Ajani JA, Venook AP. Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov; 1(6 Suppl):S8-S12. PMID: 19330060; PMCID: PMC2659794.
    351. Izzo JG, Ajani JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol. 2007 Nov 01; 25(31):4865-7. PMID: 17971580.
      View in: PubMed
    352. Cen P, Ajani JA. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol. 2007 Nov; 23(6):631-5. PMID: 17906439.
      View in: PubMed
    353. Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol. 2007 Dec; 14(12):3290-2. PMID: 17932722; PMCID: PMC2077914.
    354. Ajani JA, Correa AM, Swisher SG, Wu TT. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007 Sep 20; 25(27):4315-6. PMID: 17878485.
      View in: PubMed
    355. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95. PMID: 17636525.
      View in: PubMed
    356. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24):3719-25. PMID: 17704421.
      View in: PubMed
    357. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 01; 25(22):3210-6. PMID: 17664468.
      View in: PubMed
    358. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 01; 25(22):3205-9. PMID: 17664467.
      View in: PubMed
    359. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5. PMID: 17643602.
      View in: PubMed
    360. Das P, Crane CH, Ajani JA. Current treatment for localized anal carcinoma. Curr Opin Oncol. 2007 Jul; 19(4):396-400. PMID: 17545807.
      View in: PubMed
    361. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, Goldberg RM. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Jul; 1(4):146-54. PMID: 19262703; PMCID: PMC2632523.
    362. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5. PMID: 17548685.
      View in: PubMed
    363. Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15; 109(10):1989-95. PMID: 17397035.
      View in: PubMed
    364. Sakata Y, Ajani JA, Fujii M, Hyodo I, Kim YH. Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointest Cancer Res. 2007 May; 1(3):107-14. PMID: 19262716; PMCID: PMC2632816.
    365. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol. 2007 Apr; 34(2 Suppl 1):S2-6. PMID: 17449347.
      View in: PubMed
    366. Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, Liao Z, Ajani J, Stevens C, Komaki R. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1030-5. PMID: 17398033.
      View in: PubMed
    367. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800. PMID: 17379452.
      View in: PubMed
    368. Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JH. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg. 2007 Apr; 11(4):410-9; discussion 419-20. PMID: 17436123.
      View in: PubMed
    369. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007 Aug 16; 26(38):5674-9. PMID: 17353904.
      View in: PubMed
    370. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7. PMID: 17342569.
      View in: PubMed
    371. Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? J Clin Oncol. 2007 Mar 01; 25(7):906-7; author reply 908-9. PMID: 17327615.
      View in: PubMed
    372. Ajani JA. Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res. 2007 Mar; 1(2 Suppl):S16-21. PMID: 19343156; PMCID: PMC2661559.
    373. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol. 2007 Feb 20; 25(6):698-707. PMID: 17308274.
      View in: PubMed
    374. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67. PMID: 17211865.
      View in: PubMed
    375. Wang LW, Li Q, Hua ZL, Zhou F, Keping X, Daoyan W, Yao J, Ajani J. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11. PMID: 17645844.
      View in: PubMed
    376. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9. PMID: 17289885.
      View in: PubMed
    377. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40. PMID: 17133415.
      View in: PubMed
    378. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40. PMID: 17200360.
      View in: PubMed
    379. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34. PMID: 17146785.
      View in: PubMed
    380. Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc. 2007 Jan; 65(1):70-6. PMID: 17185082.
      View in: PubMed
    381. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007 Jan; 31(1):58-64. PMID: 17197919.
      View in: PubMed
    382. Izzo JG, Luthra R, Sims-Mourtada J, Chao KS, Lee JH, Wu TT, Correa AM, Luthra M, Aggarwal B, Hung MC, Ajani JA. Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S3-6. PMID: 19360144; PMCID: PMC2666833.
    383. Hu Z, Ajani JA, Wei Q. Molecular epidemiology of gastric cancer: current status and future prospects. Gastrointest Cancer Res. 2007 Jan; 1(1):12-9. PMID: 19262698; PMCID: PMC2632516.
    384. Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5. PMID: 17178277.
      View in: PubMed
    385. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80. PMID: 17075877.
      View in: PubMed
    386. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol. 2006 Dec 01; 24(34):5473-4; author reply 5474-6. PMID: 17135655.
      View in: PubMed
    387. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006 Nov 01; 12(21):6395-402. PMID: 17085651.
      View in: PubMed
    388. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 01; 24(31):4991-7. PMID: 17075117.
      View in: PubMed
    389. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006 Nov; 5(11):2844-50. PMID: 17121931.
      View in: PubMed
    390. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 01; 12(21):6565-72. PMID: 17085672.
      View in: PubMed
    391. Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutat Res. 2006 Dec 01; 602(1-2):143-50. PMID: 17011594.
      View in: PubMed
    392. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006 Oct 01; 107(7):1475-82. PMID: 16944539.
      View in: PubMed
    393. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 01; 107(7):1467-74. PMID: 16955509.
      View in: PubMed
    394. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8. PMID: 17006988; PMCID: PMC4088233.
    395. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74. PMID: 16874819.
      View in: PubMed
    396. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs. 2006 Sep; 24(5):441-6. PMID: 16586011.
      View in: PubMed
    397. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 20; 24(24):3953-8. PMID: 16921048.
      View in: PubMed
    398. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006 Aug 15; 107(4):676-85. PMID: 16847885.
      View in: PubMed
    399. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2006 Aug 21; 95(4):450-6. PMID: 16880795; PMCID: PMC2360664.
    400. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604. PMID: 16899607.
      View in: PubMed
    401. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother. 2006 Aug; 7(12):1627-31. PMID: 16872265.
      View in: PubMed
    402. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006 Aug 01; 12(15):4590-7. PMID: 16899606.
      View in: PubMed
    403. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer. 2006 Jul 15; 107(2):221-31. PMID: 16770784.
      View in: PubMed
    404. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7. PMID: 16683077.
      View in: PubMed
    405. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10; 24(23):3789-98. PMID: 16785472.
      View in: PubMed
    406. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86. PMID: 17409902.
      View in: PubMed
    407. Ajani JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun; 33 Suppl 1:117-20. PMID: 16897985.
      View in: PubMed
    408. Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 01; 106(9):1908-16. PMID: 16568451.
      View in: PubMed
    409. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47. PMID: 16569387.
      View in: PubMed
    410. Yasui W, Ajani JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci. 2006 Apr; 97(4):328-31. PMID: 16630126.
      View in: PubMed
    411. Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2006 Apr; 4(4):375-82. PMID: 16569390.
      View in: PubMed
    412. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66. PMID: 16569388.
      View in: PubMed
    413. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9. PMID: 17409865.
      View in: PubMed
    414. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25. PMID: 16456809.
      View in: PubMed
    415. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7. PMID: 16446338.
      View in: PubMed
    416. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8. PMID: 16353210.
      View in: PubMed
    417. Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38. PMID: 16451769.
      View in: PubMed
    418. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54. PMID: 16401681.
      View in: PubMed
    419. Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer. 2006; 9(2):140-3. PMID: 16767371.
      View in: PubMed
    420. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7. PMID: 16722991.
      View in: PubMed
    421. Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005 Dec 15; 24(56):8268-76. PMID: 16170369.
      View in: PubMed
    422. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67. PMID: 16344314.
      View in: PubMed
    423. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72. PMID: 16399296.
      View in: PubMed
    424. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72. PMID: 16245310.
      View in: PubMed
    425. Shao L, Lin J, Huang M, Ajani JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. Genes Chromosomes Cancer. 2005 Dec; 44(4):415-22. PMID: 16114035.
      View in: PubMed
    426. Ajani J, Allgood V. Molecular mechanisms in cancer: what should clinicians know? Semin Oncol. 2005 Dec; 32(6 Suppl 8):2-4. PMID: 16360003.
      View in: PubMed
    427. Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, Ajani JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S11-5. PMID: 16399423.
      View in: PubMed
    428. Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S87-9. PMID: 16399440.
      View in: PubMed
    429. Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother. 2005 Dec; 6(16):2805-12. PMID: 16318431.
      View in: PubMed
    430. Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S78-81. PMID: 16399438.
      View in: PubMed
    431. Ajani JA. Introduction. Semin Oncol. 2005 Dec; 32(6 Suppl 8):1. PMID: 16360002.
      View in: PubMed
    432. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8. PMID: 16242255.
      View in: PubMed
    433. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9. PMID: 16242257.
      View in: PubMed
    434. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6. PMID: 16118804.
      View in: PubMed
    435. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602. PMID: 16134179.
      View in: PubMed
    436. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55. PMID: 16130133.
      View in: PubMed
    437. Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct; 23(5):479-84. PMID: 16133799.
      View in: PubMed
    438. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65. PMID: 16145066.
      View in: PubMed
    439. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20; 23(24):5660-7. PMID: 16110025.
      View in: PubMed
    440. Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther. 2005 Aug; 5(4):719-25. PMID: 16111471.
      View in: PubMed
    441. Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005 Aug; 140(2):325-7. PMID: 16086962.
      View in: PubMed
    442. Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005 Aug; 29(8):1079-85. PMID: 16006804.
      View in: PubMed
    443. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20. PMID: 15849517; PMCID: PMC1357136.
    444. Agarwal B, Swisher SG, Ajani J, Kelly K, Komaki RR, Abu-Hamda E, Correa AM, Roth JA. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23. PMID: 15854962.
      View in: PubMed
    445. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103. PMID: 15860869.
      View in: PubMed
    446. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):826-9. PMID: 15824151.
      View in: PubMed
    447. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 01; 103(7):1347-55. PMID: 15719440.
      View in: PubMed
    448. Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol. 2005 Jul 01; 23(19):4256-8. PMID: 15781878.
      View in: PubMed
    449. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36. PMID: 15788671.
      View in: PubMed
    450. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64. PMID: 15708243.
      View in: PubMed
    451. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44. PMID: 15718321.
      View in: PubMed
    452. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93. PMID: 15746037.
      View in: PubMed
    453. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol. 2005 Feb; 3(2):118-24. PMID: 16166979.
      View in: PubMed
    454. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Komaki R, Ajani JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7. PMID: 15680801.
      View in: PubMed
    455. Chak A, Canto MI, Isenberg GA, Willis JE. EUS assessment of response to chemoradiation in esophageal cancer patients. Am J Gastroenterol. 2005 Feb; 100(2):496-7; author reply 497-9. PMID: 15667512.
      View in: PubMed
    456. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91. PMID: 15661803.
      View in: PubMed
    457. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63. PMID: 15701853.
      View in: PubMed
    458. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28. PMID: 15747170.
      View in: PubMed
    459. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76. PMID: 16648656.
      View in: PubMed
    460. Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer. 2005; 36(1):55-8. PMID: 16227636.
      View in: PubMed
    461. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. PMID: 16368871.
      View in: PubMed
    462. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93. PMID: 15590179.
      View in: PubMed
    463. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71. PMID: 15570077.
      View in: PubMed
    464. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
      View in: PubMed
    465. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60. PMID: 15464463.
      View in: PubMed
    466. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36. PMID: 15380576.
      View in: PubMed
    467. Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10. PMID: 15300556.
      View in: PubMed
    468. Whiting J, Sano T, Sasako M, Ajani JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. Jpn J Clin Oncol. 2004 Aug; 34(8):481-8. PMID: 15371468.
      View in: PubMed
    469. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 01; 101(3):518-26. PMID: 15274064.
      View in: PubMed
    470. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
      View in: PubMed
    471. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80. PMID: 15254045.
      View in: PubMed
    472. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66. PMID: 15233663.
      View in: PubMed
    473. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17. PMID: 15217947.
      View in: PubMed
    474. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54. PMID: 15160337.
      View in: PubMed
    475. Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep. 2004 May; 6(3):192-8. PMID: 15066230.
      View in: PubMed
    476. Ajani JA. Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol. 2004 May 01; 22(9):1763-4; author reply 1764-5. PMID: 15118003.
      View in: PubMed
    477. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol. 2004 May; 34(5):282-6. PMID: 15231865.
      View in: PubMed
    478. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96. PMID: 15067027.
      View in: PubMed
    479. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004; 7(2):61-77. PMID: 15224192.
      View in: PubMed
    480. Higuchi K, Koizumi W, Tanabe S, Saigenji K, Ajani JA. Chemotherapy is more active against proximal than distal gastric carcinoma. Oncology. 2004; 66(4):269-74. PMID: 15218293.
      View in: PubMed
    481. Xiong HQ, Ajani JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev. 2004 Jan-Jun; 23(1-2):145-63. PMID: 15000155.
      View in: PubMed
    482. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43. PMID: 15209739.
      View in: PubMed
    483. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64. PMID: 16035620.
      View in: PubMed
    484. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80. PMID: 14695137.
      View in: PubMed
    485. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22. PMID: 14630268.
      View in: PubMed
    486. Vauthey JN, Ajani JA. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol. 2003 Dec 01; 21(23):4265-7. PMID: 14581443.
      View in: PubMed
    487. Ajani JA. It's the poison that killed him, you say! J Clin Oncol. 2003 Oct 15; 21(20):3885. PMID: 14551310.
      View in: PubMed
    488. Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9. PMID: 12941201.
      View in: PubMed
    489. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7. PMID: 12909224.
      View in: PubMed
    490. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2. PMID: 14569843.
      View in: PubMed
    491. Ajani JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):10-2. PMID: 14569840.
      View in: PubMed
    492. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003 Aug; 4(8):498-505. PMID: 12901965.
      View in: PubMed
    493. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7. PMID: 12967136.
      View in: PubMed
    494. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70. PMID: 12714889.
      View in: PubMed
    495. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 01; 97(5):1195-202. PMID: 12599225.
      View in: PubMed
    496. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003 Jan; 9(1):134-42. PMID: 12538461.
      View in: PubMed
    497. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003; 14 Suppl 2:ii41-4. PMID: 12810457.
      View in: PubMed
    498. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7. PMID: 14648779.
      View in: PubMed
    499. Schnirer II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol. 2003; 42(7):672-92. PMID: 14690153.
      View in: PubMed
    500. Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):14-27. PMID: 19764147.
      View in: PubMed
    501. Ajani J, D'Amico TA, Hayman JA, Meropol NJ, Minsky B. Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003 Jan; 1(1):28-39. PMID: 19764148.
      View in: PubMed
    502. Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol. 2002 Nov; 81(3):118-24; discussion 124-5. PMID: 12407722.
      View in: PubMed
    503. Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):317-26. PMID: 12243803.
      View in: PubMed
    504. Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):386-96. PMID: 12243812.
      View in: PubMed
    505. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5. PMID: 12192324; PMCID: PMC1422591.
    506. Kasakura Y, Ajani JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug; 80(4):181-5. PMID: 12210031.
      View in: PubMed
    507. Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol. 2002 Aug; 7(4):219-24. PMID: 12202975.
      View in: PubMed
    508. Ajani JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused? Ann Surg Oncol. 2002 Aug; 9(7):605-6. PMID: 12167571.
      View in: PubMed
    509. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):89-96. PMID: 12108902.
      View in: PubMed
    510. Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002 May; 4(3):222-8. PMID: 11937012.
      View in: PubMed
    511. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8. PMID: 12109800.
      View in: PubMed
    512. Kasakura Y, Ajani JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. Am Surg. 2002 May; 68(5):434-40. PMID: 12013286.
      View in: PubMed
    513. Kasakura Y, Phan A, Ajani J. Adjuvant therapy for resected gastric carcinoma. Surg Oncol Clin N Am. 2002 Apr; 11(2):431-44, xii-xiii. PMID: 12424861.
      View in: PubMed
    514. Ajani JA. [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]. Chirurg. 2002 Apr; 73(4):312-5. PMID: 12063914.
      View in: PubMed
    515. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6. PMID: 11857295.
      View in: PubMed
    516. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. PMID: 12491078.
      View in: PubMed
    517. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83. PMID: 11782772.
      View in: PubMed
    518. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer. 2002; 5 Suppl 1:31-4. PMID: 12772885.
      View in: PubMed
    519. Yao JC, Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12. PMID: 12401660.
      View in: PubMed
    520. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001 Dec; 130(6):1078-85. PMID: 11742342.
      View in: PubMed
    521. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 06; 345(10):725-30. PMID: 11547741.
      View in: PubMed
    522. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001 Jul 15; 92(2):279-86. PMID: 11466680.
      View in: PubMed
    523. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul; 8(6):519-24. PMID: 11456051.
      View in: PubMed
    524. Tebbutt NC, Norman A, Hill M, Cunningham D. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2001 May 15; 19(10):2765-7. PMID: 11352971.
      View in: PubMed
    525. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4. PMID: 11301842.
      View in: PubMed
    526. Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5. PMID: 11232959.
      View in: PubMed
    527. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27. PMID: 11641011.
      View in: PubMed
    528. Ajani J, Ettinger D, Kelsen DP, Hudis C, Kudelka A, Langer C, Pienta K, Safran H, Vokes EE, Yung WK. Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):88-91. PMID: 11641021.
      View in: PubMed
    529. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3. PMID: 11561696.
      View in: PubMed
    530. Ajani JA. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):17-8. PMID: 11200142.
      View in: PubMed
    531. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000 Dec 01; 18(23):4001-3. PMID: 11099333.
      View in: PubMed
    532. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):387-98. PMID: 12057146.
      View in: PubMed
    533. Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):19-21. PMID: 11200143.
      View in: PubMed
    534. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):34-7. PMID: 11200147.
      View in: PubMed
    535. Ajani JA. [Strategies for preoperative therapy of locoregional cancers: an opportunity for expanding current concepts]. Chirurg. 2000 Dec; 71(12):1431-2. PMID: 11195060.
      View in: PubMed
    536. Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol. 2000 Nov; 16(6):516-21. PMID: 17031130.
      View in: PubMed
    537. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1126-32. PMID: 10838528.
      View in: PubMed
    538. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho. 2000 May; 27 Suppl 2:392-4. PMID: 10895184.
      View in: PubMed
    539. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000 Mar-Apr; 6(2):78-81. PMID: 11069223.
      View in: PubMed
    540. Medgyesy CD, Wolff RA, Putnam JB, Ajani JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7. PMID: 10640955.
      View in: PubMed
    541. York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999 Dec; 6(8):771-6. PMID: 10622506.
      View in: PubMed
    542. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park). 1999 Nov; 13(11):1485-94; discussion 1497-502 passim. PMID: 10581599.
      View in: PubMed
    543. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 1999 Nov 01; 86(9):1657-68. PMID: 10547537.
      View in: PubMed
    544. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999 Aug; 17(8):2403-11. PMID: 10561303.
      View in: PubMed
    545. Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer. 1999 Jun 01; 85(11):2336-9. PMID: 10357402.
      View in: PubMed
    546. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, Ajani J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999 May; 51(2):153-60. PMID: 10435807.
      View in: PubMed
    547. Bold RJ, Ota DM, Ajani JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. Gastric Cancer. 1999 May; 2(1):1-7. PMID: 11957063.
      View in: PubMed
    548. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 Mar; 229(3):303-8. PMID: 10077040; PMCID: PMC1191693.
    549. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999 Mar-Apr; 5(2):112-4. PMID: 10198733.
      View in: PubMed
    550. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999 Feb; 17(2):600-6. PMID: 10080605.
      View in: PubMed
    551. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999; 17(7):474-8. PMID: 10518191.
      View in: PubMed
    552. Ajani JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs. 1999; 58 Suppl 3:85-90. PMID: 10711846.
      View in: PubMed
    553. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31; 339(27):1979-84. PMID: 9869669.
      View in: PubMed
    554. NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):179-223. PMID: 10028512.
      View in: PubMed
    555. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):44-7. PMID: 9830625.
      View in: PubMed
    556. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998 Aug; 16(8):2877-85. PMID: 9704742.
      View in: PubMed
    557. Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):99-102. PMID: 9726100.
      View in: PubMed
    558. Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. Gastrointest Endosc. 1998 Aug; 48(2):172-9. PMID: 9717783.
      View in: PubMed
    559. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 Jul-Aug; 4(4):269-74. PMID: 9689986.
      View in: PubMed
    560. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34. PMID: 9586897.
      View in: PubMed
    561. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998 Feb; 21(1):36-8. PMID: 9499254.
      View in: PubMed
    562. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998 Feb; 170(2):339-44. PMID: 9456942.
      View in: PubMed
    563. Thomas E, Dumas P, Ajani JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Invest New Drugs. 1998-1999; 16(4):333-5. PMID: 10426667.
      View in: PubMed
    564. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998 Jan; 113(1 Suppl):112S-119S. PMID: 9438700.
      View in: PubMed
    565. Ajani JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. Invest New Drugs. 1998; 16(2):175-7. PMID: 9848582.
      View in: PubMed
    566. Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec; 20(6):573-6. PMID: 9391543.
      View in: PubMed
    567. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PMID: 9427271.
      View in: PubMed
    568. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1996 Oct; 23(5 Suppl 12):55-8. PMID: 8941411.
      View in: PubMed
    569. Lowy AM, Mansfield PF, Leach SD, Ajani J. Laparoscopic staging for gastric cancer. Surgery. 1996 Jun; 119(6):611-4. PMID: 8650600.
      View in: PubMed
    570. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg. 1996 Feb; 20(2):147-56. PMID: 8661810.
      View in: PubMed
    571. Jeon HM, Lynch PM, Howard L, Ajani J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. Hum Mutat. 1996; 7(4):327-33. PMID: 8723682.
      View in: PubMed
    572. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol. 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PMID: 7481861.
      View in: PubMed
    573. Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct; 18(5):436-8. PMID: 7572763.
      View in: PubMed
    574. Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9. PMID: 7607922.
      View in: PubMed
    575. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995 Jun; 22(3 Suppl 6):35-40. PMID: 7541155.
      View in: PubMed
    576. Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, Ajani JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):197-204. PMID: 7721616.
      View in: PubMed
    577. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20. PMID: 7754626.
      View in: PubMed
    578. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995 Jan 15; 75(2):451-6. PMID: 7812915.
      View in: PubMed
    579. Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother. 1995; 5(3):104-11. PMID: 8528966.
      View in: PubMed
    580. Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer. 1995; 31A(5):790-3. PMID: 7640055.
      View in: PubMed
    581. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer. 1995; 31A(5):665-70. PMID: 7640036.
      View in: PubMed
    582. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994 Nov; 12(11):2296-300. PMID: 7964943.
      View in: PubMed
    583. Kelsen D, Ajani J, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Semin Oncol. 1994 Oct; 21(5 Suppl 8):44-8. PMID: 7524158.
      View in: PubMed
    584. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. Ann N Y Acad Sci. 1994 Sep 15; 733:479-87. PMID: 7978898.
      View in: PubMed
    585. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park). 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61. PMID: 7527642.
      View in: PubMed
    586. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 1994 Aug; 21(4):474-82. PMID: 8042045.
      View in: PubMed
    587. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994 Jul 20; 86(14):1086-91. PMID: 7912736.
      View in: PubMed
    588. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994 May; 5(5):468-70. PMID: 7915537.
      View in: PubMed
    589. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol. 1994 Mar; 1(2):111-6. PMID: 7834435.
      View in: PubMed
    590. Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994 Mar; 5(3):286-7. PMID: 8186177.
      View in: PubMed
    591. Vassilopoulou-Sellin R, Ajani J. Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am. 1994 Mar; 23(1):53-65. PMID: 7913029.
      View in: PubMed
    592. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994 Jan 05; 86(1):51-3. PMID: 7903699.
      View in: PubMed
    593. Ajani JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest. 1994; 12(5):488-90. PMID: 7922705.
      View in: PubMed
    594. Rich TA, Ajani JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol. 1994; 5 Suppl 3:9-15. PMID: 8204536.
      View in: PubMed
    595. Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 Suppl 3:75-80. PMID: 8204533.
      View in: PubMed
    596. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993 Dec; 114(6):1175-81; discussion 1181-2. PMID: 7903005.
      View in: PubMed
    597. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44. PMID: 8230264.
      View in: PubMed
    598. Jones DV, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer. 1993 Nov 01; 72(9):2560-3. PMID: 8402476.
      View in: PubMed
    599. Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy. 1993 Nov; 25(9):587-91. PMID: 8119209.
      View in: PubMed
    600. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 01; 71(11):3690-6. PMID: 8490919.
      View in: PubMed
    601. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol. 1993 Jun; 27(3):209-15. PMID: 8210457.
      View in: PubMed
    602. Pazdur R, Ajani JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer. 1993 Feb 15; 71(4):1214-8. PMID: 8435795.
      View in: PubMed
    603. Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb; 11(1):67-9. PMID: 8349439.
      View in: PubMed
    604. Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer. 1993; 29A(16):2332-3. PMID: 7509166.
      View in: PubMed
    605. Jones DV, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest. 1993; 11(6):667-9. PMID: 8221199.
      View in: PubMed
    606. Ajani JA. In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol. 1993 Jan; 11(1):193-4. PMID: 8418233.
      View in: PubMed
    607. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1993 Jan; 11(1):22-8. PMID: 8418237.
      View in: PubMed
    608. Ajani JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. Semin Oncol. 1992 Dec; 19(6 Suppl 14):45-7. PMID: 1488653.
      View in: PubMed
    609. Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec; 15(6):524-7. PMID: 1449117.
      View in: PubMed
    610. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992 Oct 15; 70(8):2073-6. PMID: 1394037.
      View in: PubMed
    611. Jones DV, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med. 1992 Sep; 93(3):348-9. PMID: 1524091.
      View in: PubMed
    612. Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug; 10(3):211-3. PMID: 1428730.
      View in: PubMed
    613. Grossie VB, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol. 1992 Jul; 50(3):161-7. PMID: 1619938.
      View in: PubMed
    614. Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs. 1992 Apr; 10(1):39-42. PMID: 1376722.
      View in: PubMed
    615. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992 Feb 15; 69(4):878-82. PMID: 1735078.
      View in: PubMed
    616. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992; 28A(4-5):880-4. PMID: 1524915.
      View in: PubMed
    617. Grossie VB, Ota DM, Ajani JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. Invest New Drugs. 1991 Nov; 9(4):321-6. PMID: 1804805.
      View in: PubMed
    618. Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6. PMID: 1804812.
      View in: PubMed
    619. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs. 1991 Nov; 9(4):369-71. PMID: 1804816.
      View in: PubMed
    620. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991 Oct 01; 68(7):1501-6. PMID: 1893349.
      View in: PubMed
    621. Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med. 1991 Aug; 115(8):807-12. PMID: 1713759.
      View in: PubMed
    622. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. Invest New Drugs. 1991 Aug; 9(3):257-9. PMID: 1783525.
      View in: PubMed
    623. Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. J Surg Oncol. 1991 Jun; 47(2):117-20. PMID: 2062082.
      View in: PubMed
    624. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5. PMID: 1846848.
      View in: PubMed
    625. Dhingra K, Talpaz M, Dhingra HM, Ajani JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. Invest New Drugs. 1991 Feb; 9(1):37-9. PMID: 1851142.
      View in: PubMed
    626. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer. 1991 Jan 01; 67(1 Suppl):260-5. PMID: 1984825.
      View in: PubMed
    627. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec; 8(12):2027-31. PMID: 2230894.
      View in: PubMed
    628. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod. 1990 Oct; 9(5):522-7. PMID: 2123922.
      View in: PubMed
    629. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul; 8(7):1231-8. PMID: 2358838.
      View in: PubMed
    630. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990 Jul; 8(7):1246-54. PMID: 2193120.
      View in: PubMed
    631. Rich TA, Hughes L, Ajani JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):710. PMID: 2318708.
      View in: PubMed
    632. Venkatesh S, Ordonez NG, Ajani J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990 Jan 15; 65(2):354-7. PMID: 2153046.
      View in: PubMed
    633. Ajani JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21. PMID: 2149834.
      View in: PubMed
    634. Roth JA, Ajani JA, Rich TA. Multidisciplinary therapy for esophageal cancer. Adv Surg. 1990; 23:239-60. PMID: 2403459.
      View in: PubMed
    635. Nicaise C, Ajani J, Goudeau P, Rozencweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1990; 26(3):221-2. PMID: 1694112.
      View in: PubMed
    636. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147-59. PMID: 2400936.
      View in: PubMed
    637. Ajani JA, Ota DM, Grossie VB, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol. 1990; 26(3):223-6. PMID: 2113439.
      View in: PubMed
    638. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1153-60. PMID: 2599903.
      View in: PubMed
    639. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am. 1989 Dec; 18(4):923-30. PMID: 2559037.
      View in: PubMed
    640. Grossie VB, Nishioka K, Chang TH, Patenia D, Benitez MM, Ajani JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec; 13(6):590-5. PMID: 2515305.
      View in: PubMed
    641. Ajani JA, Ota DM, Grossie VB, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res. 1989 Oct 15; 49(20):5761-5. PMID: 2507135.
      View in: PubMed
    642. Ajani JA. Bolus fluorouracil for metastatic colorectal carcinoma? J Clin Oncol. 1989 Sep; 7(9):1366-7. PMID: 2769332.
      View in: PubMed
    643. Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol. 1989 Aug; 12(4):335-8. PMID: 2667325.
      View in: PubMed
    644. Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. Cancer Res. 1989 Aug 01; 49(15):4159-62. PMID: 2501023.
      View in: PubMed
    645. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989 Aug; 87(2):221-4. PMID: 2527006.
      View in: PubMed
    646. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15; 49(14):4057-61. PMID: 2500234.
      View in: PubMed
    647. Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Ajani J, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumours. Baillieres Clin Endocrinol Metab. 1989 May; 3(1):121-52. PMID: 2679521.
      View in: PubMed
    648. Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod. 1989 Apr; 8(2):140-6. PMID: 2499663.
      View in: PubMed
    649. Tueni EA, Newman RA, Baker FL, Ajani JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. Cancer Res. 1989 Mar 01; 49(5):1099-102. PMID: 2465080.
      View in: PubMed
    650. Ajani JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol. 1989; 24(1):41-4. PMID: 2720890.
      View in: PubMed
    651. Nishioka K, Grossie VB, Ajani JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. Int J Cancer. 1988 Nov 15; 42(5):744-7. PMID: 3141298.
      View in: PubMed
    652. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988 Nov; 6(11):1703-7. PMID: 3141592.
      View in: PubMed
    653. Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). J Biol Response Mod. 1988 Oct; 7(5):438-46. PMID: 3141591.
      View in: PubMed
    654. Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. JPEN J Parenter Enteral Nutr. 1988 Sep-Oct; 12(5):441-4. PMID: 3141639.
      View in: PubMed
    655. Fan D, Baker FL, Khokhar AR, Ajani JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res. 1988 Jun 01; 48(11):3135-9. PMID: 3365698.
      View in: PubMed
    656. Ajani JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85. PMID: 3170133.
      View in: PubMed
    657. Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr; 6(1):47-50. PMID: 2457566.
      View in: PubMed
    658. Baker FL, Ajani J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. Int J Cell Cloning. 1988 Mar; 6(2):95-105. PMID: 3373036.
      View in: PubMed
    659. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988 Mar; 108(3):340-4. PMID: 2449109.
      View in: PubMed
    660. Baker FL, Spitzer G, Ajani JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). Prog Clin Biol Res. 1988; 276:105-17. PMID: 3174675.
      View in: PubMed
    661. Ajani JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol. 1987 Dec; 5(12):1912-21. PMID: 3681375.
      View in: PubMed
    662. Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol. 1987 Oct; 23(10):1469-76. PMID: 2890527.
      View in: PubMed
    663. Odaimi M, Ajani J. High-dose chemotherapy. Concepts and strategies. Am J Clin Oncol. 1987 Apr; 10(2):123-32. PMID: 3551575.
      View in: PubMed
    664. Ajani JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1987 Apr; 10(2):139-40. PMID: 3551577.
      View in: PubMed
    665. Grossie VB, Ota DM, Ajani JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. Cancer Res. 1987 Apr 01; 47(7):1836-40. PMID: 3102050.
      View in: PubMed
    666. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987 Jan 15; 47(2):403-6. PMID: 3491676.
      View in: PubMed
    667. Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer. 1986 Oct; 54(4):607-13. PMID: 3778805; PMCID: PMC2001502.
    668. Odaimi M, Ajani JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med J. 1986 Oct; 79(10):1304-6. PMID: 2429372.
      View in: PubMed
    669. Patt YZ, Boddie AW, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol. 1986 Sep; 4(9):1356-64. PMID: 2943876.
      View in: PubMed
    670. Ota DM, Grossie VB, Ajani JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. Int J Cancer. 1986 Aug 15; 38(2):245-9. PMID: 3089944.
      View in: PubMed
    671. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986 Jul; 147(1):149-54. PMID: 2424291.
      View in: PubMed
    672. Schosser RH. Toxic reaction to prolonged high-dose fluorouracil. JAMA. 1986 Jun 13; 255(22):3116. PMID: 2939267.
      View in: PubMed
    673. Adolphson CC, Ajani JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1986 Jun; 9(3):189-91. PMID: 3728371.
      View in: PubMed
    674. Ajani JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep. 1986 Mar; 70(3):375-9. PMID: 3955548.
      View in: PubMed
    675. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 1986 Mar; 46(3):1263-74. PMID: 3484678.
      View in: PubMed
    676. Ajani JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. Invest New Drugs. 1986; 4(2):141-8. PMID: 2426218.
      View in: PubMed
    677. Ajani JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs. 1986; 4(4):383-5. PMID: 3583645.
      View in: PubMed
    678. Umbach GE, Spitzer G, Ajani JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. J Cancer Res Clin Oncol. 1986; 111(3):273-6. PMID: 3733857.
      View in: PubMed
    679. Hortobagyi GN, Papadoupoulos NE, Frye D, Ajani J, Reuben JM. Phase I clinical study of nafazatrom. Invest New Drugs. 1986; 4(3):251-5. PMID: 3818230.
      View in: PubMed
    680. Feldman LD, Ajani JA. Fluorouracil-associated dermatitis of the hands and feet. JAMA. 1985 Dec 27; 254(24):3479. PMID: 2933539.
      View in: PubMed
    681. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res. 1985 Jun; 38(6):592-8. PMID: 3925242.
      View in: PubMed
    682. Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28. PMID: 3998518.
      View in: PubMed
    683. Ajani JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. Am J Clin Oncol. 1985 Feb; 8(1):69-71. PMID: 3993626.
      View in: PubMed
    684. Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology. 1985; 42(2):69-71. PMID: 3921891.
      View in: PubMed
    685. Ajani JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol. 1985; 13 Suppl 16:95-100. PMID: 2580731.
      View in: PubMed
    686. Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, Ajani JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol. 1985; 109(2):130-4. PMID: 3980561.
      View in: PubMed
    687. Ajani JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. Cancer Treat Rep. 1984 Dec; 68(12):1507-8. PMID: 6595058.
      View in: PubMed
    688. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984 Sep; 68(9):1085-91. PMID: 6478448.
      View in: PubMed
    689. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984 Aug; 44(8):3608-12. PMID: 6744283.
      View in: PubMed
    690. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      View in: PubMed
    691. Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, Ajani J, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. Recent Results Cancer Res. 1984; 94:253-66. PMID: 6593776.
      View in: PubMed
    692. Kanojia M, Kantarjian H, Ajani J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. Br J Cancer. 1983 Dec; 48(6):869-71. PMID: 6652028; PMCID: PMC2011573.
    693. Legha SS, Ajani JA, Bodey GP. Phase I study of spirogermanium given daily. J Clin Oncol. 1983 May; 1(5):331-6. PMID: 6668504.
      View in: PubMed
    694. Ajani JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. Cancer Treat Rep. 1982 Nov; 66(11):1987-9. PMID: 6890408.
      View in: PubMed
    695. Ajani JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. Cancer Treat Rep. 1982 May; 66(5):1227-8. PMID: 6805950.
      View in: PubMed
    696. In reply [19]. Journal of Clinical Oncology. 23:3870-3871.
    697. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology. 23:626-632.
    698. Role of chemotherapy for advanced/recurrent gastric cancer. JAMA - Journal of the American Medical Association. 49:1565-1577.
    699. Cancer single pathways inhibitors. Gastric and Breast Cancer. 11:111-117.
    700. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer. EBioMedicine. 13:113-124.
    701. American Society of Clinical Oncology, 45th Annual Meeting - Comparison of cisplatin/S-1 tablets with cisplatin/5-FU infusions for advanced gastric cancer. P and T. 34:379-380.
    702. Erratum. Cancer. 115:2024.
    703. Seminars in Oncology. Seminars in Oncology. 32:1.
    704. How much luminal dilation (if any) is necessary prior to placement of an esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
    705. Management of a rectovesical malignant fistula with the coated wallstent. Gastrointestinal Endoscopy. 45.
    706. Erratum. Cancer. 120:3264.
    707. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials.
    708. A nomogram to predict distant metastases after multimodality therapy for patients with localized esophageal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 14:173-179.
    709. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology.
    710. Palliation of malignant colorectal strictures with expandable metallic stents. Gastrointestinal Endoscopy. 47.
    711. Editor's commentary. Current Colorectal Cancer Reports. 1:1.
    712. Gastrointestinal malignancies in the elderly. Cancer Bulletin. 47:218-223.
    713. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
    714. Adjuvant therapy for resected gastric carcinoma. Surgical Oncology Clinics of North America. 11:431-444.
    715. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clinic Proceedings. 91:1307-1318.
    716. The biology of K-Ras and B-Raf mutations in colorectal cancer. Current Colorectal Cancer Reports. 6:206-211.
    717. Seminars in oncology. Seminars in Oncology. 29:1-2.
    718. Survival rates in T1 and T2 gastric cancer. Journal of Surgical Oncology. 114:602-606.
    719. Reply to D. Vordermark. Journal of Clinical Oncology. 27:3065.
    720. Adjuvant chemotherapy of colorectal cancer. Cancer Bulletin. 40:235-238.
    721. In Reply. JAMA - Journal of the American Medical Association. 255:3116.
    722. Barrett's esophagus. Gastrointestinal Cancer Research. 5:49-53.
    723. In reply [2]. Journal of Clinical Oncology. 25:5529-5530.
    724. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. American Journal of Dermatopathology. 21:36-38.
    725. Surgical Resection first for localized gastric adenocarcinoma. Journal of Clinical Oncology. 33:3085-3091.
    726. Corrigendum to "Docetaxel-related side effects and their management" [European Journal of Oncology Nursing 12 (2008) 253-268] (DOI. European Journal of Oncology Nursing. 12:479.
    727. Conservative management of anal and low rectal cancers with combined modality therapy. Cancer Bulletin. 41:71-74.
    728. Status of newer chemotherapeutic strategies for the treatment of metastatic gastric cancer. American Journal of Cancer. 4:65-70.
    729. Erratum. Current Opinion in Gastroenterology. 24:101.
    730. Neoadjuvant therapy for gastric cancer. Asian Journal of Surgery. 24:235-241.
    731. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology. 1-11.
    732. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology. 1-6.
    733. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy. Oncology (Switzerland). 91:55-60.
    734. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology (Switzerland).
    735. The role of docetaxel in gastric cancer. European Journal of Cancer, Supplement. 4:4-9.
    736. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.
    737. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma. Archives of Pathology and Laboratory Medicine. 140:1345-1363.
    738. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 14:1286-1312.
    739. Outcome of preoperative chemoradiation in localized gastric adenocarcinoma. American Journal of Hematology/ Oncology. 6:142-145.
    740. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs. 3:737-746.
    741. Development and validation of a six-gene recurrence risk score assay for gastric cancer. Clinical Cancer Research. 22:6228-6235.
    742. Introduction. Seminars in Oncology. 34.
    743. Adjuvant and neoadjuvant therapy for gastric cancer. Gastrointestinal Cancer Research. 5:203-204.
    744. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology (Switzerland).
    745. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. Clinical Gastroenterology and Hepatology. 13:1730-1737.
    746. The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. 143-150.
    747. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Review of Proteomics. 13:1041-1053.
    748. In reply. Journal of Clinical Oncology. 27:468-469.
    749. GCR graduates from nursery school on a fast track to editorial excellence. Gastrointestinal Cancer Research. 4:39.
    750. Introduction. Seminars in Oncology. 33:1.
    751. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Annals of Surgical Oncology.
    752. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. The Lancet Oncology. 17:1628-1629.
    753. Early clinical esophageal adenocarcinoma (cT1). European Journal of Radiology. 88:56-60.
    754. Paraneoplastic neurological syndromes associated with gastric cancer. Clinical Journal of Gastroenterology. 5:355-360.
    755. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 64:1721-1731.
    756. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Review of Gastroenterology and Hepatology. 10:383-392.
    757. Response. Gastrointestinal Endoscopy. 76:1073-1075.
    758. Gastroesophageal cancers. 3-4.
    759. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice. 9:463-471.
    760. Adhesive tumor cell culture system.
    761. Anal canal cancer. Expert Opinion on Orphan Drugs. 2:137-146.
    762. Management of advanced gastric cancer.
    763. The overall complication rate after esophageal Wallstent is related to the esophageal location of the lesion. Gastrointestinal Endoscopy. 45.
    764. Esophageal Adenocarcinoma. 67-86.
    765. Tumor factors that may affect the outcome after palliation with the esophageal Wallstent?. Gastrointestinal Endoscopy. 45.
    766. In reply [5]. Journal of Clinical Oncology. 25:2491-2493.
    767. Therapeutic options for patients with advanced islet cell and carcinoid tumors. Regional Cancer Treatment. 3:235-242.
    768. Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma. Gastroenterology. 149:1599-1606.
    769. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 6:25883-25896.
    770. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Annals of Surgical Oncology. 1-8.
    771. Author reply [4]. Cancer. 109:1449.
    772. Operative and adjuvant treatment strategies for gastric carcinoma. Cancer Bulletin. 44:286-291.
    773. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Annals of Surgical Oncology. 1-6.
    774. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Annals of Surgical Oncology. 1-6.
    775. 1988 American Society of Clinical Oncology Meeting (ASCO 1988) - New Orleans, May 23-25, 1988. Journal of Cancer Research and Clinical Oncology. 114:533-535.
    776. Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointestinal Endoscopy. 47.
    777. Group organizational structure. International Journal of Radiation Oncology Biology Physics. 51:6-10.
    778. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer.
    779. The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. Annals of Translational Medicine. 4.
    780. The emerging epidemic of gastroesophageal cancers. Oncology. 21.
    781. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. Journal of Gastrointestinal Oncology. 6:45-52.
    782. The role of PI3K/PTEN/AKT/mTOR genetic variation in clinical outcomes following chemoradiotherapy for esophageal cancer. American Journal of Hematology/ Oncology. 8.
    783. Palliation of malignant dysphagia with chemoradiation therapy (ChXRT) does not increase the rate of serious complications with coated Wallstent. Gastrointestinal Endoscopy. 45.
    784. Activity of investigational agents.
    785. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer. Journal of Gastrointestinal Oncology. 7:499-505.
    786. Global chemotherapy development for gastric cancer. Gastric Cancer. 1-10.
    787. Palliation of malignant dysphagia and fistulae with the Wwallstent. Gastrointestinal Endoscopy. 45.
    788. In reply. Gastrointestinal Cancer Research. 3:218.
    789. Chemotherapy and radiotherapy for anal canal carcinoma - Reply. JAMA - Journal of the American Medical Association. 300:1411.
    790. Genome-based diagnostics and therapeutics in personalized cancer therapy. Gastric and Breast Cancer. 11:53-57.
    791. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation. Oncology (Switzerland).
    792. Seminars in Oncology. Seminars in Oncology. 32.
    793. In reply. Journal of Clinical Oncology. 26:2236-2237.
    794. Is targeted therapy possible for patients with gastric adenocarcinoma?. Expert Opinion on Pharmacotherapy. 1-4.
    795. Oxaliplatin beim kolorektal-karzinom. Onkologie. 25:1-11.
    796. Phase I study of spirogermanium (SPG) given for five consecutive days per week.
    AJANI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description